Factors of compliance in patients with hypercholesterolemia using rosuvastatin in primary care

Korean Journal of Family Medicine

Volumn 33, Issue 5, 2012, Pages 253-261

  Kim, Hye Young ^a   Lee, Jung Ah ^a   Kim, Young Sik ^a   Sunwoo, Sung ^a   Oh, Han Jin ^b   Kim, Chang Sup ^c   Yum, Keunsang ^d   Choi, Changjin ^e   Jeong, Yoo Seock ^f   Song, Sang Wook ^g   Kim, Dae Hyun ^h   Kim, Young Sung ⁱ  

^a University of Ulsan College of Medicine   (South Korea)

^b Kwandong University College of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Uijeongbu St Mary's Hospital   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f Dankook University College of Medicine   (South Korea)

^g The Catholic University of Korea   (South Korea)

^h Dongsan Medical Center   (South Korea)

ⁱ National Health Insurance Corporation   (South Korea)

Author keywords

Compliance; Hypercholesterolemia; Lipid lowering therapy; Rosuvastatin

Indexed keywords

EID: 84872583093     PISSN: 20056443     EISSN: 20926715     Source Type: Journal    
DOI: 10.4082/kjfm.2012.33.5.253     Document Type: Article

References (20)

1. Statistics Korea. Results of statistics of causes of death in 2009 [Internet]. Daejeon: Statistics Korea; 2010 [cited 2010 Sep 9]. Available from: http://www.kosis.kr/wnsearch/totalSearch.jsp.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
4. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-32.
5. Luvai A, Mbagaya W, Hall AS, Barth JH. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol 2012;6:17-33.
6. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61.
7. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
8. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996;164:208-11.
9. Tonkin AM, Colquhoun D, Emberson J, Hague W, Keech A, Lane G, et al. Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. Lancet 2000;356:1871-5.
10. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004;19:638-45.
11. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-31.
12. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279:1458-62.
13. Kiortsis DN, Giral P, Bruckert E, Turpin G. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther 2000;25:445-51.
14. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J 1997;18:1718-24.
15. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147-52.
16. Mann DM, Allegrante JP, Natarajan S, Halm EA, Charlson M. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther 2007;21:311-6.
17. Kim YS, Sunwoo S, Lee HR, Lee KM, Park YW, Shin HC, et al. Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients. Pharmacoepidemiol Drug Saf 2002;11:593-600.
18. Wisniowska B, Skowron A. Evaluation of patients ' adherence to statins in Poland. Curr Med Res Opin 2011;27:99-105.
19. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
20. Petrilla AA, Benner JS, Battleman DS, Tierce JC, Hazard EH. Evidence-based interventions to improve patient compliance with antihypertensive and lipid-lowering medications. Int J Clin Pract 2005;59:1441-51.